Compare
Side by side
Pick up to three peptides to see how their mechanisms, studied uses and evidence levels differ. Rows where the entries disagree are marked with a blue edge.
Selected 1 of 3
Comparison
DSIP
Cognitive & neuro
Evidence level
Anecdotal evidence
Approval status
Not approved
Mechanism of action
- 1.Originally named for its ability to increase delta-wave (slow-wave) sleep in animal experiments.
- 2.Reported to influence the hypothalamic-pituitary-adrenal axis and reduce stress-hormone release in some studies.
- 3.May affect opioid and GABA-related signalling, based on animal pharmacology.
- 4.Its exact receptor and primary mechanism have never been clearly identified, which is a major limitation.
Studied for
- Insomnia and sleep architecture
- Chronic pain, including migraine and fibromyalgia (small trials)
- Withdrawal and dependency states (small trials)
- Stress-hormone response
Reported effects
- Some small trials reported improved sleep quality and increased slow-wave sleep
- Results were inconsistent and often not reproduced
- Reported analgesic effects in a few small studies
- No modern, adequately powered trial has confirmed any of these
Side effects
- Reported as generally well tolerated in old trials
- Headache, nausea and dizziness reported occasionally
- Long-term safety never assessed
- Unverified product quality in unregulated supply
Research protocol
Research context only — no approved protocol exists. Older studies used intravenous or intranasal microgram-to-milligram doses in small groups over days. These figures are historical research details, not guidance.
Research context only
Evidence justification
The literature consists of small, old studies with inconsistent and largely unreplicated results, no clear mechanism, and no modern controlled trials.